Clinical experience with spironolactone in pediatrics

Annals of Pharmacotherapy

Volumn 39, Issue 5, 2005, Pages 823-828

  Buck, Marcia L ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Children; Chronic lung disease; Heart disease; Infants; Spironolactone

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLOROTHIAZIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROCHLOROTHIAZIDE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; POTASSIUM CHLORIDE; SPIRONOLACTONE; TACROLIMUS; THIAZIDE DIURETIC AGENT; TRIMETHOPRIM;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HEART DISEASE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; INFANT; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEWBORN; PEDIATRICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUPPLEMENTATION;

CHRONIC DISEASE; DIAGNOSIS-RELATED GROUPS; DIURETICS; FEMALE; HEART DISEASES; HUMANS; HYPERKALEMIA; HYPOKALEMIA; INFANT; LUNG DISEASES; MALE; POTASSIUM; PROSPECTIVE STUDIES; SPIRONOLACTONE;

EID: 17644388479     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E618     Document Type: Article

References (24)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17. DOI 10.1056/NEJM1999909023411001
2. Walker RD, Cumming GR. Response of the infant kidney to diuretic drugs. Can Med Assoc J 1964;91:1149-53.
3. Sole J, Knorr D. [Effect of aldosterone and spironolactone on urinary sodium and potassium excretion in newborns and infants] German. Z Kinderheilkd 1974;116:143-52.
4. Sonntag J. [Effect of dexamethasone and spironolactone therapy on diuresis and creatinine clearance in premature infants with a birth weight below 1,500 g] German. Klin Padiatr 1996;208:319-22.
5. Sonntag J, Gaude M. [Effect of dexamethasone and spironolactone therapy in calcium and phosphate homeostasis in premature infants with a birth weight under 1,500 g] German. Klin Padiatr 1998;210:354-7.
6. Kao LC, Warburton D, Cheng MH, Cedeno C, Platzker ACG, Keens TG. Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: results of a double-blind crossover sequential trial. Pediatrics 1984;74:37-44.
7. Kao LC, Durand DJ, Phillips BL, Nickerson BG. Oral theophylline and diuretics improve pulmonary mechanics in infants with bronchopulmonary dysplasia. J Pediatr 1987;111:439-44.
8. Albersheim SG, Solimano AJ, Sharma AK, Smyth JA, Rotschild A, Wood BJ, et al. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. J Pediatr 1989;115:615-20.
9. Engelhart B, Blalock WA, DonLevy S, Rush M, Hazinski TA. Effect of spironolactone-hydrochlorothiazide on lung function in infants with chronic bronchopulmonary dysplasia. J Pediatr 1989;114:619-24.
10. Kao LC, Durand DJ, McCrea RC, Birch M, Powers RJ, Nickerson BG. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. J Pediatr 1994;124:772-81.
11. Hoffman DJ, Gerdes JS, Abbasi S. Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: a double-blind, placebo-controlled, randomized trial. J Perinatol 2000;1:41-5.
12. Wimmer M, Bachl G, Schlemmer M, Stiskal A. [Experience with aldactone in pediatric cardiology] German. Padiatr Padol 1979;14:363-72.
13. Baylen BG, Johnson G, Tsang R, Srivastava L, Kaplan S. The occurrence of hyperaldosteronism in infants with congestive heart failure. Am J Cardiol 1980;45:305-10.
14. Hobbins SM, Fowler RS, Rowe RD, Korey AG. Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease. Arch Dis Child 1981;56:934-8.
15. Danks DM. Diuretic therapy in infants and children (letter). J Pediatr 1976;88:695-6.
16. Ringel RE, Peddy SB. Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease. Am J Cardiol 2003;91:1031-2. DOI 10.1016/S0002-9149(03)00135-8
17. Department of Health and Human Services, National Institutes of Health. List of drugs for which pediatric studies are needed. Fed Reg 2003;68:2789-90. http://frwebgate.access.gpo (accessed 2004 Nov 22).
18. Allen LV, Erickson MA. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Am J Health Syst Pharm 1996;53:2073-8.
19. Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook. 11th ed. Hudson, OH: Lexi-Comp, 2004:1098-100.
20. Veronica L, ed. Harriet Lane handbook: a manual for pediatric house officers. 16th ed. Philadelphia: Mosby, 2002:846-7.
21. Bell GM, Fananapazir L, Anderton H. Comparison of single and divided daily dose spironolactone in the control of hypertension (letter). Br J Clin Pharmacol 1981;12:585-8.
22. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51. DOI 10.1056/NEJMoa040135
23. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585-92. DOI 10.1056/NEJMra035279
24. Bozkurt B, Igoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003;41:211-4.